Gene Logic Says Review Confirms That Genomics Unit Is Weak, Drug Repositioning Has Legs | GenomeWeb
NEW YORK (GenomeWeb News) – Gene Logic today said that an internal business review confirmed that the firm's genomics business is weak and that the drug-repositioning business is poised to grow.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.